Thomas Gidoin Joins OSE Immunotherapeutics as Chief Financial Officer
August 20, 2025 - 23:13
NANTES, France, August 20, 2025 – OSE Immunotherapeutics SA has officially announced the appointment of Thomas Gidoin as its new Chief Financial Officer. With over 15 years of extensive experience in capital markets and financial strategy, Gidoin brings a wealth of knowledge and expertise to the company’s Executive Committee.
Gidoin's background in biopharma finance is marked by a strong track record in strategic financial leadership, which he has demonstrated in both private and public sectors. His appointment is anticipated to enhance OSE Immunotherapeutics' financial governance and strategic initiatives, positioning the company for future growth and success.
The addition of Gidoin to the leadership team is seen as a pivotal move to strengthen the company's financial operations and align its strategies with the evolving landscape of the biopharmaceutical industry. Stakeholders and investors alike are looking forward to the insights and direction he will bring in his new role.
MORE NEWS
August 23, 2025 - 03:56
Stocks Surge Following Dovish Remarks from Fed ChairA variety of stocks saw significant gains in the afternoon trading session, driven by a rebound in major indices. This uptick followed comments from Federal Reserve Chair Jerome Powell at the...
August 22, 2025 - 03:59
Kaldalón hf. Reports Strong Financial Performance for First Half of 2025The interim consolidated financial statements for the first half of 2025 have been officially approved by Kaldalón hf.`s Board of Directors on August 21, 2025. The company has reported impressive...
August 21, 2025 - 11:57
James Hardie Industries Reports Disappointing First Quarter Earnings for 2026James Hardie Industries has released its first quarter earnings report for the fiscal year 2026, revealing results that fell short of analyst expectations. The company, known for its fiber cement...
August 20, 2025 - 06:28
Second Quarter Earnings Reports Show Mixed ResultsThe gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive. However, not all companies have fared well. La...